Certificates Processing System: Demo & Q&A session for Industry stakeholders (H+V), Online, from 27 March 2025, 12:30 (CET) to 27 March 2025, 13:00 (CET)

Certificates Processing System: Demo & Q&A session for Industry stakeholders (H+V), Online, from 27 March 2025, 12:30 (CET) to 27 March 2025, 13:00 (CET)

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Date of authorisation: 03/12/2010, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Date of authorisation: 03/12/2010, Revision: 23, Status: Authorised

Orphan designation: Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (darvadstrocel) Treatment of anal fistula, 08/10/2009 Withdrawn

Orphan designation: Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (darvadstrocel) Treatment of anal fistula, 08/10/2009 Withdrawn

Human medicines European public assessment report (EPAR): Regkirona, regdanvimab, Date of authorisation: 12/11/2021, Revision: 9, Status: Withdrawn

Human medicines European public assessment report (EPAR): Regkirona, regdanvimab, Date of authorisation: 12/11/2021, Revision: 9, Status: Withdrawn

Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 7: Submission of other post-authorisation data

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 7: Submission of other post-authorisation data

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.